Uso de antipsicóticos y su asociación con enfermedad tromboembólica venosa en pacientes adultos
Barra lateral del artículo
Contenido principal del artículo
##plugins.themes.bootstrap3.displayStats.downloads##
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010; 341:c4245.
Parkin L, Skegg DC, Herbison GP, et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf. 2003; 12:647-52.
Wu CS, Lin CC, Chang CM, et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Clin Psychiatry. 2013; 74:918-24.
Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol. 2013; 33:753-8.
Ishiguro C,Wang X, Li L, et al. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD. Pharmacoepidemiol Drug Saf. 2014; 23:1168-75.
Ishioka M, Yasui-Furukori N, Sugawara N, et al. Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatr Dis Treat. 2015; 11:477-84.
Jönsson AK, Spigset O, Hägg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs. 2012; 26:649-62.
Ferraris A, Szmulewicz AG, Vázquez FJ, et al. Antipsychotic Use among Adult Outpatients and Venous Thromboembolic Disease. A Retrospective Cohort Study. J Clin Psychopharmacol. 2017; 37(4):405-11.